Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, PA / ACCESS New ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), ...
All animal studies were performed according to protocols approved by the University Committee on Animal Resources at the University of Rochester Medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results